- Home
- RDI vs KZR Comparison
RDI vs KZR Comparison
Compare RDI & KZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDI
- KZR
- Stock Information
- Founded
- RDI 1937
- KZR 2015
- Country
- RDI United States
- KZR United States
- Employees
- RDI N/A
- KZR N/A
- Industry
- RDI Movies/Entertainment
- KZR Biotechnology: Pharmaceutical Preparations
- Sector
- RDI Consumer Discretionary
- KZR Health Care
- Exchange
- RDI Nasdaq
- KZR Nasdaq
- Market Cap
- RDI 35.7M
- KZR 29.7M
- IPO Year
- RDI N/A
- KZR 2018
- Fundamental
- Price
- RDI $1.53
- KZR $3.85
- Analyst Decision
- RDI
- KZR Hold
- Analyst Count
- RDI 0
- KZR 2
- Target Price
- RDI N/A
- KZR $9.00
- AVG Volume (30 Days)
- RDI 55.7K
- KZR 30.5K
- Earning Date
- RDI 11-13-2025
- KZR 11-11-2025
- Dividend Yield
- RDI N/A
- KZR N/A
- EPS Growth
- RDI N/A
- KZR N/A
- EPS
- RDI N/A
- KZR N/A
- Revenue
- RDI $219,213,000.00
- KZR N/A
- Revenue This Year
- RDI $5.21
- KZR N/A
- Revenue Next Year
- RDI $11.45
- KZR N/A
- P/E Ratio
- RDI N/A
- KZR N/A
- Revenue Growth
- RDI 7.59
- KZR N/A
- 52 Week Low
- RDI $1.17
- KZR $3.62
- 52 Week High
- RDI $1.88
- KZR $9.18
- Technical
- Relative Strength Index (RSI)
- RDI 56.79
- KZR 43.61
- Support Level
- RDI $1.47
- KZR $3.76
- Resistance Level
- RDI $1.60
- KZR $4.05
- Average True Range (ATR)
- RDI 0.07
- KZR 0.14
- MACD
- RDI -0.01
- KZR -0.01
- Stochastic Oscillator
- RDI 42.86
- KZR 31.82
About RDI Reading International Inc
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About KZR Kezar Life Sciences Inc.
Kezar Life Sciences Inc is a clinical-stage biotechnology company. It is engaged in discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer. The pipeline consist of product candidates such as Zetomipzomib (KZR-616), and KZR-261.